Welcome to our dedicated page for Ultragenyx Pharm news (Ticker: RARE), a resource for investors and traders seeking the latest updates and insights on Ultragenyx Pharm stock.
Ultragenyx Pharmaceutical Inc. develops and commercializes therapies for serious rare and ultra-rare genetic diseases. Company news commonly covers revenue from approved medicines such as Crysvita, Dojolvi, and Mepsevii, financial guidance, and updates to a portfolio of approved therapies and product candidates for diseases with high unmet medical need and clear biology.
Recurring developments include FDA interactions and clinical data for investigational programs such as UX111 for Sanfilippo syndrome type A, GTX-102 for Angelman syndrome, UX016 for GNE myopathy, and AAV gene therapy candidates for rare metabolic disorders. Updates also include healthcare conference participation, employment inducement equity grants under Nasdaq rules, and corporate restructuring or expense-management actions when disclosed.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Ultragenyx Pharmaceutical (NASDAQ: RARE) has announced the grant of stock options and restricted stock units to 11 newly hired non-executive officers. The grant includes 11,035 stock options and 17,710 restricted stock units, approved by the compensation committee and awarded under the Ultragenyx Employment Inducement Plan.
The stock options have a ten-year term with an exercise price of $38.20 per share, reflecting the closing price on April 14, 2023. The restricted stock units vest over four years, while the stock options vest at the first anniversary and continue monthly thereafter, contingent on continuous employment.
Ultragenyx focuses on developing novel therapies for rare diseases, aiming to address high unmet medical needs.